Menu
Search
|

Menu

Close
X

ESSA Pharma Inc EPIX.OQ (NASDAQ Stock Exchange Capital Market)

3.00 USD
-- (--)
As of Nov 16
chart
Previous Close 3.00
Open --
Volume --
3m Avg Volume 1,813
Today’s High --
Today’s Low --
52 Week High 5.83
52 Week Low 2.08
Shares Outstanding (mil) 29.10
Market Capitalization (mil) 10.60
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-1.871
FY17
-3.330
FY16
-9.876
FY15
-10.958
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.59
Price to Sales (TTM)
vs sector
--
5.69
Price to Book (MRQ)
vs sector
--
5.11
Price to Cash Flow (TTM)
vs sector
--
23.52
Total Debt to Equity (MRQ)
vs sector
--
15.71
LT Debt to Equity (MRQ)
vs sector
--
11.53
Return on Investment (TTM)
vs sector
-82.10
15.05
Return on Equity (TTM)
vs sector
-1,251.29
16.62

EXECUTIVE LEADERSHIP

Richard Glickman
Chairman of the Board, Since 2016
Salary: --
Bonus: --
David Parkinson
President, Chief Executive Officer, Director, Since 2016
Salary: --
Bonus: --
David Wood
Chief Financial Officer, Since
Salary: --
Bonus: --
Peter Virsik
Chief Operating Officer, Executive Vice President, Since 2016
Salary: --
Bonus: --
Raymond Andersen
Chief Technology Officer, Director, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

999 Broadway W Suite 720
VANCOUVER   BC   V5Z 1K5

Phone: +1778.3310962

ESSA Pharma Inc. is a Canada-based clinical-stage development pharmaceutical company. The Company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer (CRPC). The Company is developing drugs, which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR). The Company's product candidate, EPI-506 is a selective, oral small molecule pro-drug that blocks the N-terminal domain of the AR. EPI-506 is a pro-drug of EPI-002, a stereoisomer of the Company's discovery compound, EPI-001. The Company is conducting a Phase I/II clinical study to determine the safety, tolerability, maximum tolerated dose, pharmacokinetics and efficacy of EPI-506 in patients with metastatic CRPC. It is focused on developing EPI-506 as its clinical-development product candidate. ESSA Pharmaceuticals Corp. is the Company's subsidiary. The Company has not generated any revenues.

SPONSORED STORIES